Literature DB >> 9788431

Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase.

M Liedtke1, P Pandey, S Kumar, S Kharbanda, D Kufe.   

Abstract

The oncogenic Bcr-Abl variant of the c-Abl tyrosine kinase transforms cells by a mechanism dependent on activation of the stress-activated protein kinase (SAPK). Other work has shown that c-Abl interacts with the SHPTP1 protein tyrosine phosphatase in induction of SAPK activity by genotoxic stress. The present studies demonstrate that Bcr-Abl binds constitutively to SHPTP1. We show that Bcr-Abl phosphorylates SHPTP1 on C-terminal Y536 and Y564 sites. The functional significance of the Bcr-Abl/SHPTP1 interaction is supported by the finding that SHPTP1 regulates Bcr-Abl-induced SAPK activity. Importantly, SHPTP1 also decreases Bcr-Abl-dependent transformation of fibroblasts. These findings indicate that SHPTP1 functions as a tumor suppressor in cells transformed by Bcr-Abl.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9788431     DOI: 10.1038/sj.onc.1202117

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  BCR/ABL inhibition by an escort/phosphatase fusion protein.

Authors:  Y M Lim; S Wong; G Lau; O N Witte; J Colicelli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

2.  CIP2A is overexpressed and involved in the pathogenesis of chronic myelocytic leukemia by interacting with breakpoint cluster region-Abelson leukemia virus.

Authors:  Juandong Wang; Tao Huang; Jianzhi Sun; Yuan Yu; Zhifang Liu; Wenjuan Li; Jihui Jia; Chunyan Chen
Journal:  Med Oncol       Date:  2014-07-15       Impact factor: 3.064

Review 3.  Chronic myeloid leukemia: mechanisms of blastic transformation.

Authors:  Danilo Perrotti; Catriona Jamieson; John Goldman; Tomasz Skorski
Journal:  J Clin Invest       Date:  2010-07-01       Impact factor: 14.808

4.  A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemia.

Authors:  Ji Hoon Jung; Miyong Yun; Eun-Jeong Choo; Sun-Hee Kim; Myoung-Seok Jeong; Deok-Beom Jung; Hyemin Lee; Eun-Ok Kim; Nobuo Kato; Bonglee Kim; Sanjay K Srivastava; Kunihiro Kaihatsu; Sung-Hoon Kim
Journal:  Br J Pharmacol       Date:  2015-06-04       Impact factor: 8.739

Review 5.  ABL tyrosine kinases: evolution of function, regulation, and specificity.

Authors:  John Colicelli
Journal:  Sci Signal       Date:  2010-09-14       Impact factor: 8.192

Review 6.  Molecular biology of chronic myeloid leukemia.

Authors:  Y Maru
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

7.  PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.

Authors:  Tasneem Motiwala; Sarmila Majumder; Kalpana Ghoshal; Huban Kutay; Jharna Datta; Satavisha Roy; David M Lucas; Samson T Jacob
Journal:  J Biol Chem       Date:  2008-11-07       Impact factor: 5.157

Review 8.  ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia.

Authors:  D Perrotti; P Neviani
Journal:  Br J Cancer       Date:  2006-09-05       Impact factor: 7.640

9.  Role and mechanism of decitabine combined with tyrosine kinase inhibitors in advanced chronic myeloid leukemia cells.

Authors:  Li-Cai Jiang; Jian-Min Luo
Journal:  Oncol Lett       Date:  2017-06-06       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.